Arachidonic acid in psoriasis. Pathogenic role and pharmacological regulation
- PMID: 3010612
Item in Clipboard
Arachidonic acid in psoriasis. Pathogenic role and pharmacological regulation
Acta Derm Venereol Suppl (Stockh).
1985.
Abstract
AA and its derivatives are a family of potent mediators and regulators of inflammation. There are several pieces of evidence to suggest a pathophysiologic role of certain AA derivatives in psoriasis. The complexity of the pathways in the generation of LTs and other LO products suggests that carefully designed systems will be needed to establish the exact role of these compounds in the pathogenesis of diseases such as psoriasis, and to test the effects of pharmacological inhibitors.
Similar articles
-
[Leukotrienes and monohydroxy fatty acids: controversial role in the pathogenesis of psoriasis].Hautarzt. 1985 May;36(5):255-8. Hautarzt. 1985. PMID: 2989218 German.
-
Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses.Arch Dermatol. 1983 Jul;119(7):541-7. Arch Dermatol. 1983. PMID: 6305285 No abstract available.
-
Cutaneous responses to lipoxygenase products of arachidonic acid.Acta Derm Venereol Suppl (Stockh). 1985;120:18-22. Acta Derm Venereol Suppl (Stockh). 1985. PMID: 3010613 No abstract available.
-
[The potential and significance of pharmacologic effects on leukotrienes and other lipoxygenase derivatives of arachidonic acid].Vnitr Lek. 1987 May;33(5):502-7. Vnitr Lek. 1987. PMID: 3037786 Review. Czech. No abstract available.
-
[Leukotrienes and other products of lipoxygenases. Nature and biological profile].Acta Physiol Pharmacol Latinoam. 1985;35(1):67-92. Acta Physiol Pharmacol Latinoam. 1985. PMID: 2998154 Review. Spanish. No abstract available.
Cited by
-
Biochemical and pharmacological properties of a new topical anti-inflammatory compound, 9-phenylnonanohydroxamic acid (BMY 30094).Agents Actions. 1990 Jun;30(3-4):443-50. doi: 10.1007/BF01966310. Agents Actions. 1990. PMID: 2117339
-
A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile.Clin Investig. 1993 Aug;71(8):634-43. doi: 10.1007/BF00184491. Clin Investig. 1993. PMID: 8219661 Clinical Trial.
-
Combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor with a glucocorticoid results in synergistic topical antiinflammatory activity without inducing skin atrophy.Inflammation. 1993 Oct;17(5):531-6. doi: 10.1007/BF00914191. Inflammation. 1993. PMID: 8225561
MeSH terms
Substances
LinkOut - more resources
Medical